you can also search for UK trials via NIHR Be Part of Research (www.bepartofresearch.nihr.ac.uk) Do not discontinue any existing prescribed medication (such as semaglutide or tirzepatide) in anticipation of retatrutide becoming available For clinicians: Familiarise yourself with the LY3437943 development code and ongoing Phase 3 trial data, as patients may present with questions informed by media coverage Be prepared to discuss the distinction between investigational and approved therapies , and the importance of evidence-based prescribing Monitor MHRA and NICE communications for updates on regulatory submissions and technology appraisals From a safety perspective, the adverse effect profile observed in Phase 2 trials (as reported in the 2023 New England Journal of Medicine publication) was broadly consistent with other GLP-1-based therapies, with nausea, vomiting, diarrhoea, and decreased appetite being the most commonly reported side effects
10.1016/j.jconrel.2019.08.017 81
Theres not much preliminary data that makes me worried
Fleming Island Northeast Florida Our Fleming Island patients often ask for a fast, in-office way to support the energy and metabolism side of their weight-loss plan between visits
Do you aim patients towards those resources
These are encouraging results for anyone whose weight is literally painful and restricting their mobility